scholarly journals Validity of 2 Hour Continuous Hepatic Arterial Infusion Chemotherapy with Low Dose of 5-FU for Unresectable Liver Metastases from Colorectal Cancer.

2001 ◽  
Vol 62 (2) ◽  
pp. 346-352
Author(s):  
Hiroshi OHTANI ◽  
Hiroji NISHINO ◽  
Nobuya YAMADA ◽  
Sadatoshi SHIMIZU ◽  
Tamahiro NISHIHARA ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Liver Metastases ◽  
Low Dose ◽  
Hepatic Arterial Infusion ◽  
Hepatic Arterial Infusion Chemotherapy ◽  
Arterial Infusion ◽  
Arterial Infusion Chemotherapy ◽  
Infusion Chemotherapy ◽  
Unresectable Liver Metastases

Irinotecan Hepatic Arterial Infusion Chemotherapy for Hepatic Metastases from Colorectal Cancer: Results of a Phase I Clinical Study

2001 ◽  
Vol 87 (6) ◽  
pp. 388-390 ◽  
Author(s):  
Giammaria Fiorentini ◽  
Silvia Ricci Lucchi ◽  
Petros Giovanis ◽  
Maurizio Cantore ◽  
Stefano Guadagni ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Liver Metastases ◽  
Phase Ii ◽  
Active Drug ◽  
Hepatic Arterial Infusion ◽  
Hepatic Arterial Infusion Chemotherapy ◽  
Arterial Infusion ◽  
Arterial Infusion Chemotherapy ◽  
Infusion Chemotherapy ◽  
Phase Ii Studies

Background Hepatic arterial infusion chemotherapy is a promising approach in liver metastases from colorectal cancer, but chemical hepatitis, biliary sclerosis, arterial thrombosis and right upper quadrant pain are limiting factors. Irinotecan (CPT-11) is an active drug in colorectal cancer. We planned a short hepatic arterial infusion of CPT-11 to describe the toxicity, to determine the dose-limiting toxicity, and to define the doses of CPT-11 to be recommended for phase II studies. Patients and Methods Fourteen patients with a median liver substitution of 30% (10-60%) were enrolled. All patients received hepatic arterial infusion chemotherapy with CPT-11 on an outpatient basis every 3 weeks as a short, 30-min infusion. Results At 240 mg/m2, 2 of 4 patients experienced grade 4 diarrhea and neutropenia, and 3 of them also reported grade 4 abdominal pain of the right upper quadrant. The maximum tolerated dose was reached at 240 mg/m2. The recommended doses of CPT-11 for phase II studies is 200 mg/m2, given every 3 weeks. Conclusions CPT-11 presents a low hepatic toxic profile and could be considered a new active drug, suitable for hepatic arterial infusion in liver metastases from colorectal cancer.

Sign in / Sign up

Export Citation Format

Share Document